February 8, 2017
Lilly’s expands use of Trulicity for type 2 diabetes patiens
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 8, 2017
Amgen’s Parsabiv passes in USA
Amgen has been given green light in the USA for its Parsabiv, the cure for chronic kidney disease patients on hemodialysis to treat secondary hyperparathyroidism (HPT).
February 8, 2017
Lundbeck gives up on Alzheimer’s drug, rival to Axovant pill
Two remaining late-stage clinical trials testing an experimental Alzheimer’s drug from Denmark’s Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments.
February 8, 2017
Lysogene raises €22.6 million, focuses on developing two drugs for deadly CNS diseases
French biotechnology company Lysogene has kicked off well with its initial public offering on Euronext Paris stock market by raising €22.6 million.
February 8, 2017
MDxHealth to supply Department of Veterans Affairs with prostate cancer drug
US Government Services Administration (GSA) has awarded MDxHealth to supply Department of Veterans Affairs (VA) with ConfirmMDx for Prostate Cancer.
February 8, 2017
Onxeo clarifies its liver cancer study information
Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, issued press release to clarify information regarding the Relive trial design and conduct and, in particular, the role of its Data Safety and Monitoring Board (DSMB).
February 8, 2017
FDA bans Kingsway Trading’s dietary supplements for containing forbidden ingredient
Kingsway Trading of Brooklyn, NY is recalling its 1.06 oz (30g) bottles of “Well Balance Xanthium & Siler Combo (Bi Yan Pian)” Batch No. 130401 & Batch No. 150201 because they contain the presence of undeclared Ephedra Herba (ma huang), an FDA banned item, FDA said.
February 8, 2017
Allergy Therapeutics appoints Abbott’s Licensing and Acquisitions Vice President to its Board
Allergy Therapeutics has appointed Jeff Barton to the Company’s Board as a Non-Executive Director, nominated by Abbott Laboratories in replacement of Mr Jean-Yves Pavee who retires from the Board, both effective after close of business 7 February 2017.
February 8, 2017
OptiBiotix to trade new shares on AIM (London)
OptiBiotix Health has been notified by from warrant holders to exercise warrants over 16,351 ordinary shares
February 8, 2017
Sanofi’s 2016 income slightly down
Sanofi has reported net income of €1,6 billion for Q4 2016 which is 6% down compared to the same period last year. The full year income was €7.3 billion, 0.9% down from the last year.